Legend Biotech to Participate in the 41st Annual JP Morgan Healthcare Conference

Legend Biotech to Participate in the 41st Annual JP Morgan Healthcare Conference




Legend Biotech to Participate in the 41st Annual JP Morgan Healthcare Conference

SOMERSET, N.J.–(BUSINESS WIRE)–Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases today announced its participation in the 41st annual JP Morgan Healthcare Conference in San Francisco, CA.

CEO Ying Huang, PhD will deliver the company presentation on Tuesday, January 10, 2023 at 2:15 pm (Pacific Time).

About Legend Biotech

Legend Biotech is a global biotechnology company dedicated to treating, and one day curing, life-threatening diseases. Headquartered in Somerset, New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell and natural killer (NK) cell-based immunotherapy. From our three R&D sites around the world, we apply these innovative technologies to pursue the discovery of cutting-edge therapeutics for patients worldwide.

Learn more at www.legendbiotech.com and follow us on Twitter and LinkedIn.

Contacts

Investor Contacts:
Joanne Choi, Senior Manager, Investor Relations, Legend Biotech

joanne.choi@legendbiotech.com

Crystal Chen, Manager, Investor Relations, Legend Biotech

crystal.chen@legendbiotech.com

Press Contact:
Tina Carter, Corporate Communications Lead, Legend Biotech

tina.carter@legendbiotech.com
(908) 331-5025